Table of Contents Author Guidelines Submit a Manuscript
Surgery Research and Practice
Volume 2014, Article ID 497478, 6 pages
http://dx.doi.org/10.1155/2014/497478
Research Article

Utility of Preoperative CA125 Assay in the Management Planning of Women Diagnosed with Uterine Cancer

Portsmouth Cancer Centre, Queen Alexandra Hospital, Southwick Hill Road, Cosham, Portsmouth, Hampshire PO6 3LY, UK

Received 30 October 2013; Accepted 15 January 2014; Published 27 February 2014

Academic Editor: Giampiero Capobianco

Copyright © 2014 N. Povolotskaya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Statistics OfN, Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2008, England, 2010.
  2. Unit WCIaS, Cancer Incidence in Wales 2005–2009, edited by Unit WCIaS, 2011.
  3. ISD Online NHS Scotland IaSD, Cancer Incidence, Mortality and Survival data, 2010.
  4. P. D. Sasieni, J. Shelton, N. Ormiston-Smith, C. S. Thomson, and P. B. Silcocks, “What is the lifetime risk of developing cancer: the effect of adjusting for multiple primaries,” British Journal of Cancer, vol. 105, no. 3, pp. 460–465, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. P. Coleman, B. Rachet, L. M. Woods et al., “Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001,” British Journal of Cancer, vol. 90, no. 7, pp. 1367–1373, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. W. J. Louwman, M. J. Aarts, S. Houterman, F. J. van Lenthe, J. W. W. Coebergh, and M. L. G. Janssen-Heijnen, “A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status,” British Journal of Cancer, vol. 103, no. 11, pp. 1742–1748, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. M. Ueda, D. S. Kapp, M. K. Cheung et al., “Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths,” American Journal of Obstetrics and Gynecology, vol. 198, no. 2, pp. 218.e1–218.e6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. International Agency for Reseach on Cancer, GLOBOCAN 2008 v, IARC, European age-standardised rates calculated by the Statistical Information Team at Cancer Research UK, 2011.
  9. W. Creasman, “Revised FIGO staging for carcinoma of the endometrium,” International Journal of Gynaecology & Obstetrics, vol. 105, no. 2, p. 109, 2009. View at Publisher · View at Google Scholar
  10. G. Plataniotis, M. Castiglione, and ESMO Guidelines Working Group, “Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, supplement 5, pp. v41–v5, 2010. View at Publisher · View at Google Scholar
  11. R. Woolas and D. Oram, “Current developments in the management of endometrial cancer,” in The Year Book of the RCOG, pp. 181–193, 1994. View at Google Scholar
  12. J. V. Bokhman, “Two pathogenetic types of endometrial carcinoma,” Gynecologic Oncology, vol. 15, no. 1, pp. 10–17, 1983. View at Google Scholar · View at Scopus
  13. H. B. Salvesen, S. L. Carter, M. Mannelqvist et al., “Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 12, pp. 4834–4839, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. W. T. Creasman, M. F. Kohler, F. Odicino, P. Maisonneuve, and P. Boyle, “Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium,” Gynecologic Oncology, vol. 95, no. 3, pp. 593–596, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. C. P. Morrow, B. N. Bundy, R. J. Kurman et al., “Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study,” Gynecologic Oncology, vol. 40, no. 1, pp. 55–65, 1991. View at Publisher · View at Google Scholar · View at Scopus
  16. C. L. Creutzberg, W. L. J. van Putten, C. C. Wárláin-Rodenhtiis et al., “Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1234–1241, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Manfredi, P. Mirk, G. Maresca et al., “Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning,” Radiology, vol. 231, no. 2, pp. 372–378, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Kinkel, Y. Kaji, K. K. Yu et al., “Radiologic staging in patients with endometrial cancer: a meta-analysis,” Radiology, vol. 212, no. 3, pp. 711–718, 1999. View at Google Scholar · View at Scopus
  19. T. D. Barwick, A. G. Rockall, D. P. Barton, and S. A. Sohaib, “Imaging of endometrial adenocarcinoma,” Clinical Radiology, vol. 61, no. 7, pp. 545–555, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. A. N. Gordon, A. C. Fleischer, B. S. Dudley et al., “Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography (US) and magnetic resonance imaging (MRI),” Gynecologic Oncology, vol. 34, no. 2, pp. 175–179, 1989. View at Google Scholar · View at Scopus
  21. E. Steiner, O. Eicher, J. Sagemüller et al., “Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the department of obstetrics and gynecology of the mainz university,” International Journal of Gynecological Cancer, vol. 13, no. 2, pp. 197–203, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Sanjuán, T. Cobo, J. Pahisa et al., “Preoperative and intraoperative assessment of myometrial invasion and histologic grade in endometrial cancer: role of magnetic resonance imaging and frozen section,” International Journal of Gynecological Cancer, vol. 16, no. 1, pp. 385–390, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. G. H. Eltabbakh, J. Shamonki, and S. L. Mount, “Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors,” Gynecologic Oncology, vol. 99, no. 2, pp. 309–312, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Vorgias, J. Lekka, M. Katsoulis, E. Varhalama, N. Kalinoglou, and T. Akrivos, “Diagnostic accuracy of prehysterectomy curettage in determining tumor type and grade in patients with endometrial cancer,” Medscape General Medicine, vol. 5, no. 4, 2003. View at Google Scholar · View at Scopus
  25. X. Wang, Z. Huang, W. Di, and Q. Lin, “Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients,” Archives of Gynecology and Obstetrics, vol. 272, no. 2, pp. 136–141, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Thanachaiviwat, C. Thirapakawong, C. Leelaphatanadit, and T. Chuangsuwanich, “Accuracy of preoperative curettage in determining tumor type and grade in endometrial cancer,” Journal of the Medical Association of Thailand, vol. 94, no. 7, pp. 766–771, 2011. View at Google Scholar · View at Scopus
  27. J. Mitchard and L. Hirschowitz, “Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens,” Histopathology, vol. 42, no. 4, pp. 372–378, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. T. G. Stovall, G. J. Photopulos, W. M. Poston, F. W. Ling, and L. G. Sandles, “Pipelle endometrial sampling in patients with known endometrial carcinoma,” Obstetrics and Gynecology, vol. 77, no. 6, pp. 954–956, 1991. View at Google Scholar · View at Scopus
  29. A. G. Daniel and W. A. Peters, “Accuracy of office and operating room curettage in the grading of endometrial carcinoma,” Obstetrics and Gynecology, vol. 71, no. 4, pp. 612–614, 1988. View at Google Scholar · View at Scopus
  30. L. A. Hardesty, J. H. Sumkin, M. E. Nath et al., “Use of preoperative MR imaging in the management of endometrial carcinoma: cost analysis,” Radiology, vol. 215, no. 1, pp. 45–49, 2000. View at Google Scholar · View at Scopus
  31. I. B. Engelsen, I. M. Stefansson, L. A. Akslen, and H. B. Salvesen, “GATA3 expression in estrogen receptor α-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival,” American Journal of Obstetrics and Gynecology, vol. 199, no. 5, pp. 543.e1–543.e7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. I. B. Engelsen, I. Stefansson, L. A. Akslen, and H. B. Salvesen, “Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas,” American Journal of Obstetrics and Gynecology, vol. 195, no. 4, pp. 979–986, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. M. B. Silverman, P. C. Roche, R. M. Kho, G. L. Keeney, H. Li, and K. C. Podratz, “Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma,” Gynecologic Oncology, vol. 77, no. 1, pp. 1–7, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Oreskovic, D. Babic, D. Kalafatic, D. Barisic, and L. Beketic-Oreskovic, “A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma,” Gynecologic Oncology, vol. 93, no. 1, pp. 34–40, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Trovik, E. Wik, I. Stefansson et al., “Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer,” Histopathology, vol. 57, no. 4, pp. 641–646, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. I. B. Engelsen, I. M. Stefansson, R. Beroukhim et al., “HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas,” International Journal of Oncology, vol. 32, no. 2, pp. 307–316, 2008. View at Google Scholar · View at Scopus
  37. E. Wik, J. Trovik, O. E. Iversen et al., “Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting,” American Journal of Obstetrics and Gynecology, vol. 201, no. 6, pp. 603.e1–603.e7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. R. C. Bast, T. L. Klug, E. S. John et al., “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer,” New England Journal of Medicine, vol. 309, no. 15, pp. 883–887, 1983. View at Google Scholar · View at Scopus
  39. R. C. Bast, M. Feeney, H. Lazarus, L. M. Nadler, R. B. Colvin, and R. C. Knapp, “Reactivity of a monoclonal antibody with human ovarian carcinoma,” The Journal of Clinical Investigation, vol. 68, no. 5, pp. 1331–1337, 1981. View at Google Scholar · View at Scopus
  40. A. Berchuck, A. P. Soisson, D. L. Clarke-Pearson et al., “Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential,” Cancer Research, vol. 49, no. 8, pp. 2091–2095, 1989. View at Google Scholar · View at Scopus
  41. J. M. Niloff, T. L. Klug, E. Schaetzl, V. R. Zurawski, R. C. Knapp, and R. C. Bast, “Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix,” American Journal of Obstetrics and Gynecology, vol. 148, no. 8, pp. 1057–1058, 1984. View at Google Scholar · View at Scopus
  42. M. Santala, A. Talvensaari-Mattila, and A. Kauppila, “Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer,” Anticancer Research, vol. 23, no. 3, pp. 3097–3103, 2003. View at Google Scholar · View at Scopus
  43. J. L. Powell, K. A. Hill, B. C. Shiro, S. J. Diehl, and W. H. Gajewski, “Preoperative serum CA-125 levels in treating endometrial cancer,” The Journal of Reproductive Medicine, vol. 50, no. 8, pp. 585–590, 2005. View at Google Scholar · View at Scopus
  44. Y. Todo, N. Sakuragi, R. Nishida et al., “Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma,” American Journal of Obstetrics and Gynecology, vol. 188, no. 5, pp. 1265–1272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Kukura, G. Zovko, S. Ciglar et al., “Serum CA-125 tumor marker in endometrial adenocarcinoma,” European Journal of Gynaecological Oncology, vol. 24, no. 2, pp. 151–153, 2003. View at Google Scholar · View at Scopus
  46. S. Ginath, J. Menczer, Y. Fintsi, E. Ben-Shem, M. Glezerman, and I. Avinoach, “Tissue and serum CA125 expression in endometrial cancer,” International Journal of Gynecological Cancer, vol. 12, no. 4, pp. 372–375, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. D. J. Dotters, “Preoperative CA 125 in endometrial cancer: is it useful?” American Journal of Obstetrics and Gynecology, vol. 182, no. 6, pp. 1328–1334, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Jhang, L. Chuang, P. Visintainer, and G. Ramaswamy, “CA 125 levels in the preoperative assessment of advanced-stage uterine cancer,” American Journal of Obstetrics and Gynecology, vol. 188, no. 5, pp. 1195–1197, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Takeshima, Y. Shimizu, S. Umezawa et al., “Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma,” Gynecologic Oncology, vol. 54, no. 3, pp. 321–326, 1994. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Yildiz, H. Yetimalar, B. Kasap et al., “Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma,” European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 164, no. 2, pp. 191–195, 2012. View at Publisher · View at Google Scholar
  51. C.-H. Hsieh, C.-C. ChangChien, H. Lin et al., “Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer?” Gynecologic Oncology, vol. 86, no. 1, pp. 28–33, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. J. T. Soper, A. Berchuck, G. J. Olt, A. P. Soisson, D. L. Clarke-Pearson, and R. C. Bast, “Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma,” American Journal of Obstetrics and Gynecology, vol. 163, no. 4, pp. 1204–1209, 1990. View at Google Scholar · View at Scopus
  53. H. S. Kim, C.-Y. Park, J.-M. Lee et al., “Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study,” Gynecologic Oncology, vol. 118, no. 3, pp. 283–288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. B. P. Goksedef, H. Gorgen, S. Y. Baran, M. Api, and A. Cetin, “Preoperative serum CA 125 level as a predictor for metastasis and survival in endometrioid endometrial cancer,” Journal of Obstetrics and Gynaecology Canada, vol. 33, no. 8, pp. 844–850, 2011. View at Google Scholar
  55. I. Takac and B. Gorisek, “Serum CA 125 levels and lymph node metastasis in patients with endometrial cancer,” Wiener Klinische Wochenschrift, vol. 118, no. 2, supplement, pp. 62–65, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. N. P. Koper, L. F. Massuger, C. M. Thomas, L. A. Kiemeney, and A. L. Verbeek, “Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy,” Anticancer Research, vol. 18, no. 3, pp. 1897–1902, 1998. View at Google Scholar · View at Scopus
  57. A. K. Sood, R. E. Buller, R. A. Burger, J. D. Dawson, J. I. Sorosky, and M. Berman, “Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome,” Obstetrics and Gynecology, vol. 90, no. 3, pp. 441–447, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. S. M. Smith and M. S. Hoffman, “The role of vaginal hysterectomy in the treatment of endometrial cancer,” American Journal of Obstetrics and Gynecology, vol. 197, no. 2, pp. 202.e1–202.e7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. J. K. Chan, Y. G. Lin, B. J. Monk, K. Tewari, J. D. Bloss, and M. L. Berman, “Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women,” Obstetrics and Gynecology, vol. 97, no. 5, part 1, pp. 707–711, 2001. View at Google Scholar · View at Scopus
  60. W. T. Creasman, C. P. Morrow, B. N. Bundy, H. D. Homesley, J. E. Graham, and P. B. Heller, “Surgical pathologic spread patterns of endometrial cancer: a gynecologic oncology group study,” Cancer, vol. 60, supplement 8, pp. 2035–2041, 1987. View at Google Scholar · View at Scopus
  61. G. A. Viani, B. F. Patia, A. C. Pellizzon et al., “High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome,” Radiation Oncology, vol. 1, article 24, 2006. View at Google Scholar · View at Scopus
  62. E. L. Trimble, C. Kosary, and R. C. Park, “Lymph node sampling and survival in endometrial cancer,” Gynecologic Oncology, vol. 71, no. 3, pp. 340–343, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. H. Watari, Y. Todo, M. Takeda, Y. Ebina, R. Yamamoto, and N. Sakuragi, “Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer,” Gynecologic Oncology, vol. 96, no. 3, pp. 651–657, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. C. V. Lutman, L. J. Havrilesky, J. M. Cragun et al., “Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology,” Gynecologic Oncology, vol. 102, no. 1, pp. 92–97, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Yokoyama, H. Maruyama, S. Sato, and Y. Saito, “Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers,” Gynecologic Oncology, vol. 64, no. 3, pp. 411–417, 1997. View at Publisher · View at Google Scholar · View at Scopus
  66. M. N. Barnes and L. C. Kilgore, “Complete surgical staging of early endometrial adenocarcinoma: optimizing patient outcomes,” Seminars in Radiation Oncology, vol. 10, no. 1, pp. 3–7, 2000. View at Google Scholar · View at Scopus
  67. K. W. Lo, T. H. Cheung, M. Y. Yu, S. F. Yim, and T. K. Chung, “The value of pelvic and para-aortic lymphadenectomy in endometrial cancer to avoid unnecessary radiotherapy,” International Journal of Gynecological Cancer, vol. 13, no. 6, pp. 863–869, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. T. O. Wilson, K. C. Podratz, T. A. Gaffey, G. D. Malkasian, P. C. O'Brien, and J. M. Naessens, “Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma,” American Journal of Obstetrics and Gynecology, vol. 162, no. 2, pp. 418–426, 1990. View at Google Scholar · View at Scopus
  69. T. W. Burke, P. B. Heller, J. E. Woodward, S. A. Davidson, W. J. Hoskins, and R. C. Park, “Treatment failure in endometrial carcinoma,” Obstetrics and Gynecology, vol. 75, no. 1, pp. 96–101, 1990. View at Google Scholar · View at Scopus
  70. P. G. Rose, R. M. Sommers, F. R. Reale, R. E. Hunter, L. Fournier, and B. E. Nelson, “Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma,” Obstetrics and Gynecology, vol. 84, no. 1, pp. 12–16, 1994. View at Google Scholar · View at Scopus
  71. J. M. Duk, J. G. Aalders, G. J. Fleuren, and H. W. de Bruijn, “CA 125: a useful marker in endometrial carcinoma,” American Journal of Obstetrics and Gynecology, vol. 155, no. 5, pp. 1097–1102, 1986. View at Google Scholar · View at Scopus
  72. B. Patsner, W. J. Mann, H. Cohen, and M. Loesch, “Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma,” American Journal of Obstetrics and Gynecology, vol. 158, no. 2, pp. 399–402, 1988. View at Google Scholar · View at Scopus
  73. P. L. Cherchi, S. Dessole, G. A. Ruiu et al., “The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma,” European Journal of Gynaecological Oncology, vol. 20, no. 4, pp. 315–317, 1999. View at Google Scholar · View at Scopus
  74. T. Alagoz, R. E. Buller, M. Berman, B. Anderson, A. Manetta, and P. Disaia, “What is a normal CA125 level?” Gynecologic Oncology, vol. 53, no. 1, pp. 93–97, 1994. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Sebastianelli, M. C. Renaud, J. Grégoire, M. Roy, and M. Plante, “Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease,” Journal of Obstetrics and Gynaecology Canada, vol. 32, no. 9, pp. 856–860, 2010. View at Google Scholar · View at Scopus